Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) has been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company.
A number of research analysts have recently issued reports on HKMPF shares. reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 1st. Citigroup reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 1st. Zacks Investment Research downgraded Hikma Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, September 9th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a report on Friday, August 20th. Finally, Barclays reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a report on Thursday, September 2nd.
Shares of OTCMKTS HKMPF remained flat at $$34.30 during trading on Friday. Hikma Pharmaceuticals has a 1-year low of $30.15 and a 1-year high of $37.70. The company has a market cap of $8.31 billion, a P/E ratio of 20.06 and a beta of 0.41. The stock has a 50-day moving average price of $35.24 and a 200 day moving average price of $33.79. The company has a current ratio of 1.87, a quick ratio of 1.13 and a debt-to-equity ratio of 0.36.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa.
Recommended Story: Basic Economics creates winners and losers
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.